{"id":"efavirenz-or-nevirapine","safety":{"commonSideEffects":[{"rate":"15–20","effect":"Rash"},{"rate":"10–15","effect":"Dizziness / CNS effects (efavirenz)"},{"rate":"5–10","effect":"Hepatotoxicity"},{"rate":"5–10","effect":"Nausea"},{"rate":"5–10","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL223228","moleculeType":"Small molecule","molecularWeight":"315.68"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Both drugs bind directly to HIV reverse transcriptase and inhibit its enzymatic activity, blocking a critical step in the HIV replication cycle. They are used as components of combination antiretroviral therapy (cART) to suppress viral replication and prevent disease progression. Efavirenz and Nevirapine are distinct molecules with different pharmacokinetic profiles and resistance patterns, though both belong to the NNRTI class.","oneSentence":"Efavirenz and Nevirapine are non-nucleoside reverse transcriptase inhibitors (NNRTIs) that block HIV reverse transcriptase, preventing the virus from converting its RNA genome into DNA and replicating.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:36:06.207Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection (as part of combination antiretroviral therapy)"}]},"trialDetails":[{"nctId":"NCT02016924","phase":"PHASE2, PHASE3","title":"Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2014-01-16","conditions":"Acquired Immune Deficiency Syndrome (AIDS), HIV Infections","enrollment":133},{"nctId":"NCT06337032","phase":"PHASE4","title":"A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-08-27","conditions":"HIV-1-infection","enrollment":350},{"nctId":"NCT02302547","phase":"PHASE3","title":"Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2014-12","conditions":"HIV","enrollment":224},{"nctId":"NCT00042289","phase":"","title":"Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2003-06-09","conditions":"HIV Infections","enrollment":1578},{"nctId":"NCT05502341","phase":"PHASE2, PHASE3","title":"Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2022-08-16","conditions":"HIV-1-infection","enrollment":689},{"nctId":"NCT02285114","phase":"PHASE2, PHASE3","title":"Study To Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in Human Immunodeficiency Virus 1 (HIV-1) Infected Children and Adolescents Virologically Suppressed on a 2-Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (2-NRTI)-Containing Regimen","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-01-20","conditions":"HIV-1","enrollment":41},{"nctId":"NCT02397096","phase":"PHASE3","title":"Safety and Efficacy of a Switch to Doravirine, Tenofovir, Lamivudine (MK-1439A) in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on an Anti-retroviral Regimen in Combination With Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-06-09","conditions":"HIV-1 Infection","enrollment":673},{"nctId":"NCT01717885","phase":"","title":"Antimalarial Pharmacology in Children and Pregnant Women in Uganda","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2012-08","conditions":"Malaria, HIV","enrollment":473},{"nctId":"NCT03537196","phase":"PHASE4","title":"DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C)","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2018-11-13","conditions":"Hepatitis C, Drug Use, Viral Hepatitis C","enrollment":979},{"nctId":"NCT01789879","phase":"PHASE2","title":"A Pharmacokinetic Evaluation of Levonorgestrel Implant and Antiretroviral Therapy","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2014-03-04","conditions":"HIV, Contraception","enrollment":60},{"nctId":"NCT00260078","phase":"PHASE1, PHASE2","title":"Blood Levels of Anti-HIV Drugs Used in Combination Regimens in HIV Infected Children","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-02","conditions":"HIV Infections","enrollment":75},{"nctId":"NCT00074581","phase":"PHASE3","title":"Preventing Sexual Transmission of HIV With Anti-HIV Drugs","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-02","conditions":"HIV Infections","enrollment":3526},{"nctId":"NCT00039741","phase":"PHASE2, PHASE3","title":"Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2002-08","conditions":"HIV Infections","enrollment":266},{"nctId":"NCT00102960","phase":"PHASE3","title":"Anti-HIV Drugs for Treating Infants Who Acquired HIV Infection at Birth","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-07","conditions":"HIV Infections","enrollment":377},{"nctId":"NCT01435018","phase":"PHASE3","title":"Three Chemo Regimens as an Adjunct to ART for Treatment of Advanced AIDS-KS","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2013-10-01","conditions":"HIV-1 Infection","enrollment":334},{"nctId":"NCT03631732","phase":"PHASE3","title":"Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2018-08-28","conditions":"HIV-1 Infection","enrollment":496},{"nctId":"NCT03723525","phase":"PHASE4","title":"Package of Care to Improve Retention in ART and Mortality Among Treatment Naive HIV Infected Individuals","status":"COMPLETED","sponsor":"National Centre for AIDs and STD Control, Nepal","startDate":"2018-01-22","conditions":"HIV","enrollment":1073},{"nctId":"NCT00925756","phase":"PHASE4","title":"CCR5 Inhibitor Treatment Intensification on CD4+ T-cell Recovery","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2008-10-20","conditions":"HIV Infections","enrollment":32},{"nctId":"NCT02616029","phase":"PHASE3","title":"Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-17","conditions":"HIV-1 Infection","enrollment":66},{"nctId":"NCT02121795","phase":"PHASE3","title":"Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-05-06","conditions":"HIV-1 Infection","enrollment":668},{"nctId":"NCT02616783","phase":"PHASE3","title":"Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-22","conditions":"HIV-1 Infection","enrollment":167},{"nctId":"NCT02469246","phase":"PHASE3","title":"Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-06-29","conditions":"HIV-1 Infection","enrollment":567},{"nctId":"NCT00978068","phase":"PHASE3","title":"HIV Protease Inhibitors for the Prevention of Malaria in Ugandan Children","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2009-09","conditions":"Malaria, HIV Infections","enrollment":176},{"nctId":"NCT02605954","phase":"PHASE3","title":"Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-18","conditions":"HIV-1 Infection","enrollment":275},{"nctId":"NCT00427297","phase":"PHASE3","title":"Optimizing Pediatric HIV-1 Treatment in Infants With Prophylactic Exposure to Nevirapine, Nairobi, Kenya","status":"TERMINATED","sponsor":"University of Washington","startDate":"2007-09","conditions":"HIV Infections","enrollment":34},{"nctId":"NCT03227653","phase":"","title":"Neuropsychiatric Side Effects of Efavirenz in Children Living With HIV","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2017-06-19","conditions":"Efavirenz, Child Behavior, Cognitive Symptom","enrollment":144},{"nctId":"NCT02082652","phase":"PHASE4","title":"A Pharmacokinetic Evaluation of Etonogestrel (ENG) Implant and Antiretroviral Therapy","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2014-10","conditions":"HIV, Contraception","enrollment":60},{"nctId":"NCT00445146","phase":"PHASE2","title":"Safety of EVG+RTV Administered With Other Antiretroviral Agents for the Treatment of HIV-1 Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2007-02","conditions":"HIV Infections","enrollment":192},{"nctId":"NCT01495702","phase":"PHASE3","title":"Study to Evaluate Switching From Regimens Consisting of a Nonnucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2011-12","conditions":"Acquired Immunodeficiency Syndrome, HIV Infections","enrollment":439},{"nctId":"NCT01908660","phase":"","title":"Hepatic Safety of Currently Used Antiretroviral Regimens in Patients With Chronic Hepatitis Under Real Life Conditions","status":"COMPLETED","sponsor":"Valme University Hospital","startDate":"2007-01","conditions":"Human Immunodeficiency Virus, Hepatitis B, Chronic, Hepatitis C, Chronic","enrollment":192},{"nctId":"NCT01192035","phase":"PHASE4","title":"PI or NNRTI as First-line Treatment of HIV in West Africa - the PIONA Trial","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2011-05","conditions":"HIV-1","enrollment":400},{"nctId":"NCT02028676","phase":"PHASE4","title":"Efficacy Study of Different Laboratory Management Strategies and Drug Regimens in HIV-infected Children in Africa","status":"COMPLETED","sponsor":"Medical Research Council","startDate":"2007-03","conditions":"Human Immunodeficiency Virus","enrollment":1206},{"nctId":"NCT02002286","phase":"NA","title":"Safety and Efficacy Study of TwHF in HIV Patients With Poor Immune Responses","status":"COMPLETED","sponsor":"LI Taisheng","startDate":"2011-08","conditions":"HIV","enrollment":23},{"nctId":"NCT00234091","phase":"PHASE3","title":"When to Start Anti-HIV Drugs in Children Infected With HIV (The PREDICT Study)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-04","conditions":"HIV Infections","enrollment":300},{"nctId":"NCT00014937","phase":"NA","title":"Simplified Drug Regimens for HIV Patients in ACTG 388 or Patients Who Responded to A First Potent Combination Regimen","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":240},{"nctId":"NCT01817283","phase":"PHASE1, PHASE2","title":"Impact on T Cell Immune Activation and Inflammation of Triptolide Woldifii in HIV-infected Immunological Non-responders","status":"UNKNOWN","sponsor":"LI Taisheng","startDate":"2013-01","conditions":"HIV","enrollment":150},{"nctId":"NCT00966329","phase":"PHASE4","title":"Switching the Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) or Protease Inhibitor (PI) to Maraviroc in HIV Subjects","status":"COMPLETED","sponsor":"Germans Trias i Pujol Hospital","startDate":"2009-10","conditions":"HIV, HIV Infections","enrollment":30},{"nctId":"NCT00703586","phase":"PHASE1","title":"Study of the Antiviral and Immunological Effects of Intensification of Suppressive Antiretroviral Therapy With Maraviroc","status":"COMPLETED","sponsor":"Rockefeller University","startDate":"2007-09","conditions":"HIV Infections","enrollment":8},{"nctId":"NCT00495326","phase":"PHASE2, PHASE3","title":"Comparison of Nevirapine and Efavirenz for the Treatment of HIV-TB Co-infected Patients (ANRS 12146 CARINEMO)","status":"COMPLETED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2007-12","conditions":"Tuberculosis, Aids, Hiv Infections","enrollment":570},{"nctId":"NCT00168220","phase":"","title":"Predictors of Drug Hypersensitivity in HIV Infected Subjects","status":"WITHDRAWN","sponsor":"The Alfred","startDate":"2005-08","conditions":"HIV Infections, Hypersensitivity","enrollment":""},{"nctId":"NCT00523458","phase":"PHASE4","title":"A Study to Determine the Best Dose of Antivirals in Patients With Both TB and HIV","status":"TERMINATED","sponsor":"Stanford University","startDate":"2007-07","conditions":"HIV Infections, Tuberculosis","enrollment":5},{"nctId":"NCT00640887","phase":"PHASE2","title":"Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV Co-infection in South Africa","status":"COMPLETED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2009-02","conditions":"HIV Infections, Tuberculosis","enrollment":48},{"nctId":"NCT01044810","phase":"","title":"Effectiveness of Efavirenz-based Regimen in HIV-1-infected Patients With Nevirapine Hypersensitivity","status":"COMPLETED","sponsor":"Bamrasnaradura Infectious Diseases Institute","startDate":"2010-01","conditions":"Treatment Failure, HIV or AIDS, CD4 Cell Counts","enrollment":559},{"nctId":"NCT01273142","phase":"","title":"Compare to the Safety of Efavirenz and Nevirapine in Treating HIV Positive Patients With Mild Baseline Liver Function Test Impairment, and/or Hepatitis B or Hepatitis C Co-infection","status":"UNKNOWN","sponsor":"Henan Provincial People's Hospital","startDate":"2011-01","conditions":"HIV Infections, Liver Toxicity, Hepatitis Co-infection","enrollment":100},{"nctId":"NCT00620438","phase":"PHASE4","title":"Drug Interaction Between Coartem® and Nevirapine, Efavirenz or Rifampicin in HIV Positive Ugandan Patients","status":"UNKNOWN","sponsor":"Makerere University","startDate":"2008-02","conditions":"HIV Infections, Tuberculosis","enrollment":90},{"nctId":"NCT01174914","phase":"PHASE2","title":"Effectiveness Study Low-Dose Naltrexone Versus ARV's for HIV+","status":"COMPLETED","sponsor":"The Ojai Foundation","startDate":"2008-03","conditions":"HIV Seropositivity","enrollment":171}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8846,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Stocrin","Sustiva","Viramune","Sustiva (efavirenz)","Viramune (nevirapine)"],"phase":"marketed","status":"active","brandName":"Efavirenz or Nevirapine","genericName":"Efavirenz or Nevirapine","companyName":"University of Aarhus","companyId":"university-of-aarhus","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Efavirenz and Nevirapine are non-nucleoside reverse transcriptase inhibitors (NNRTIs) that block HIV reverse transcriptase, preventing the virus from converting its RNA genome into DNA and replicating. Used for HIV-1 infection (as part of combination antiretroviral therapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}